Loading clinical trials...
Loading clinical trials...
A Phase 3b Extension Study of Adjunctive ALKS 5461 in the Treatment of Refractory Major Depressive Disorder
This study will assess the long-term safety and tolerability of ALKS 5461 as an adjunctive treatment for refractory MDD.
Age
18 - 72 years
Sex
ALL
Healthy Volunteers
No
Alkermes Investigational Site
Tucson, Arizona, United States
Alkermes Investigational Site
Little Rock, Arkansas, United States
Alkermes Investigational Site
Los Alamitos, California, United States
Alkermes Investigational Site
Oceanside, California, United States
Alkermes Investigational Site
Pico Rivera, California, United States
Alkermes Investigational Site
Redlands, California, United States
Alkermes Investigational Site
Santa Ana, California, United States
Alkermes Investigational Site
Sherman Oaks, California, United States
Alkermes Investigational Site
Temecula, California, United States
Alkermes Investigational Site
Hollywood, Florida, United States
Start Date
August 9, 2018
Primary Completion Date
May 1, 2020
Completion Date
May 1, 2020
Last Updated
July 16, 2021
175
ACTUAL participants
ALKS 5461
DRUG
Lead Sponsor
Alkermes, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions